应用表皮生长因子治疗深Ⅱ度烧伤创面的远期临床疗效观察

目的　观察重组人表皮生长因子 (rhEGF)用于深Ⅱ度烧伤创面治疗的远期疗效及安全性。　方法　对 37例烧伤患者进行随机、双盲、同体对照实验 ,每例患者选择一块深Ⅱ度烧伤创面 ,并将其分为面积相近的两部分 ,于伤后第 1天开始分别用单纯等渗盐水 (对照组 )和含rhEGF的等渗盐水 (治疗组 )进行换药治疗。创面愈合后 1、4年时 ,对各患者进行院外随访 ,采用改良温哥华瘢痕测量法 ,评价上述受试创面愈合后的瘢痕指数 (SI)。　结果　 1年后随访时 ,治疗组SI为 7.19± 1.6 7,明显小于对照组 8.92± 1.78(P <0 .0 1) ;4年后随访时 ,治疗组SI为 6 .12± 1.5 4 ,明显小于对照组 8.0 9± 1.81(P <0 .0 1)。所有受试创面均无肿瘤形成、癌变等并发症发生。　结论　外用rhEGF治疗深Ⅱ度烧伤创面 ,能明显减少后期瘢痕的形成 ,远期疗效和安全性较好。

Clinical observation of the long-term effects of rhEGF on deep partial-thickness burn wounds

OBJECTIVE: To evaluate the safety and long-term effect of recombinant human epithelial growth factor (rhEGF) on deep partial-thickness burn wounds. METHODS: Thirty-seven burn patients were enrolled in this study and were observed by randomized, double-blinded and placebo-controlled protocol. An area of deep partial-thickness burn wounds from each patient was divided into control (C) and treatment (T) portions. The wound in C was treated with normal saline while that in T with rhEGF. The patients were followed-up for 1 and 4 years after wound healing. The healed wounds were evaluated by modified Vancouver scar scale in terms of scar index (SI). RESULTS: 1 year after wound healing, it was found that the SI in T group (7.19 +/- 1.67) was obviously lower than that in C group (8.92 +/- 1.78, P < 0.01). The SI in T group (6.12 +/- 1.54) was still evidently lower than that in C group (8.09 +/- 1.81, P < 0.01) four years after wound healing. There were no signs of development of tumor or cancer in all the tested burn wound areas. CONCLUSION: External application of rhEGF might be beneficial to the healing quality of deep partial-thickness burn wound with less scar formation and better long-term effects, and it is safe.